Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Oliceridine

No authors listed
In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
.
Free Books & Documents
Review

Oliceridine

No authors listed.
Free Books & Documents

Excerpt

Oliceridine is an intravenously administered, synthetic opioid that is used to treat moderate-to-severe pain not responsive to nonsteroidal antiinflammatory agents. Oliceridine is associated with a low rate of serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent liver injury.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. FDA. Integrated Review. 2020.
    1. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000M... [ (FDA Integrated review of the data on oliceridine safety and efficacy submitted in support of its application for approval as therapy of acute moderate-to-severe pain in adults mentions that ALT elevations occurred at similar rates with oliceridine as morphine, were not associated with jaundice, and were judged to be unrelated to therapy). ]
    1. Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, Rominger DH, et al. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophe n-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem. 2013;56:8019-31.(History of development of oliceridine based upon structure activity relationships to G protein biased μ opioid receptor agonism). - PubMed
    1. Wadman M. 'Biased' opioids could yield safer pain relief. Science. 2017;358(6365):847-848.(Commentary on the concept that biased opioids might be found with similar potency and analgesic effect but with less adverse events such as gastrointestinal symptoms and respiratory depression). - PubMed
    1. Viscusi ER, Skobieranda F, Soergel DG, Cook E, Burt DA, Singla N. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927-943.(Among 389 patients with moderate-to-severe pain after bunionectomy treated with a loading dose followed by patient-controlled analgesia, response rates were 50-66% with 3 doses of oliceridine, vs 71% with morphine, and 15% with placebo with no clinically meaning differences between the active treatment regimens in…clinical chemistry parameters”). - PMC - PubMed

LinkOut - more resources